Key Benefits:
Minister of the City, Youth and Sports,
Vu le Sport codeincluding article L. 232-26;
Considering the opinion of the French Doping Agency of 8 January 2015,
Stop it!
Can be subject to the criminal sanctions mentioned in I of Article L. 232-26 of the Sports Code the detention, without duly justified medical reason, of a prohibited substance or methods listed in the last paragraph of Article L. 232-9, for which Appendix 1 to the international convention referred to in Article L. 230-2 provides for the possibility of reduced sanctions only in the event of exceptional circumstances. These prohibited substances and methods are listed below:
Prohibited substances
I. - Anabolic agents:
1° Androgenic anabolic steroids (SAA):
(a) Exogenous SAA (**), including:
1-androstènediol (5α-androst-1-ène-3β,17β-diol); 1-androstènedione (5α-androst-1-ène-3,17-dione) ; bolan- diol (estr-4-ène-3β,17β-diol) ; bolaster ; boldenone ; boldione (androsta-1,4-diène-3,17-dione) ; calusterone ; closedtébol ; danazol ( [1,2] oxazolo [4',5': 2,3] pregna-4-ène-20-yn-17α-ol); dehydrochlormethyltestosterone (4- chloro-17β-hydroxy-17α-methylandrosta-1,4-diène-3-one); deoxymethyltestosterone (17α-methyl-5α-androst- 2-ène-17 β -ol); drostanolone; ethylestrenol (19-norprégna-4-ène-17α-ol) ; fluoxymesterone ; formationbolone ; ferazabol (17α-methyl [1,2.5] oxadiazolo [3',4': 2,3] -5α-androstane-17β-ol); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-ène-3-one) ; mestanolone ; mesterolone ; metandinone (17β-hydroxy-17α- methylandrosta-1,4-diène-3-one); meternolone; methandriol; methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstane-3-one); methyldenolon (17β-hydroxy-17α-methylestra-4,9-diène-3-one); methyl-1-testosterone (17β-hydroxy-17 α -methyl-5α-androst-1-ène-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); methyltestosterone; metribolone (methyltriènolone, 17β-hydroxy-17α-methylestra-4,9,11-triène-3- one) ; mibolone ; nandrolone ; 19-norandrostendione (estr-4-ene-3,17-dione); norboletone; norclostebol; Norethandrolone ; oxabolone ; oxandrolone ; oximesterone; oxymetholone; prostanozol (17β- [ (tetrahydro- pyrane-2-yl) oxy] -1'H-pyrazolo [3,4: 2,3] -5α-androstane); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-ène-3-one) ; tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-prégna- 4,9,11-triène-3-one); trenbolone (17β-hydroxyestr-4,9,11-triène-3-one);
and other substances having a similar chemical structure or a similar biological effect(s).
(b) Endogenous SAA (*) by exogenous administration (**):
Androstènediol (androst-5-ène-3β,17β-diol); androstènedione (androst-4-ène-3,17-dione); dihydrotestoste-rone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepandrosterone, DHEA, 3β-hydroxyandrost-5- ène-17-one) ; testosterone ; and the following metabolites and isomers, including without limitation:
5α-androstane-3α,17 α -diol; 5α-androstane-3α,17β-diol; 5α-androstane-3β,17 α -diol; 5α-androstane- 3β,17β-diol; 5 β -androstane-3α,17β-diol; androst-4-ene-3α,17 α -diol; androst-4-ene-3α,17β-diol; androst-4-ene-3α,17 α -diol; androst-5-ene-3α,17 α -diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17 α -diol; 4- androstendiol (androst-4-ene-3β,17β-diol); 5-androstènedione (androst-5-ène-3,17-dione) ; epi-dihydrotestos-Terona ; epitestosterone ; etiocholanolone ; 3α-hydroxy-5α-androstan-17-one; androsterone (3β-hydroxy-5α- androstan-17-one) ; 7α-hydroxy-DHEA; 7β-hydroxy-DHEA; 7-keto-DHEA; 19-norandrosterone; 19- norétiocholanolone.
2° Other anabolic agents:
Includes without limitation:
Clenbuterol, selective modulators of androgenic receptors (SARMs, e.g. andarine and ostarine), tibolone, zéranol and zilpatrol.
II. - Peptide hormones, growth factors, related and mimetic substances:
The following substances and other substances with a similar chemical structure or a similar biological effect(s) are prohibited:
1° Erythropoietin receptor agonists:
(a) Stimulating agents of erythropoiesis (ESAs) e.g. darbepoetin (DEPO); erythropoietia (EPO); EPO-Fc; methoxy polyethylene glycol-epoetin beta (CERA); mimetic peptides of EPO (EMP), e.g. CNTO 530 and petginesatide;
(b) Non-erythropoietic agonists of the EPO receptor, e.g. ARA-290 asialo-EPO and EPO carbamylée;
2° Stabilizing factors inductible by hypoxia (HIF) e.g. cobalt and FG-4592; and HIF activators e.g. xenon, argon;
3° Gonadotrophine chorionique (CG) and luteinizing hormone (LH) and their factors of liberation, e.g. busereline, gonadoreline and triptereline, prohibited in male sports only;
4° Corticotrophines and their factors of liberation, e.g. corticoreline;
5° Growth Hormone (GH) and its release factors including the growth hormone release hormone (GHRH) and its analogues, for example. CJC-1295, sermoreline and tésamoreline; growth hormone (GHS) secrettagogues, e.g. ghreline and mimetic ghreline, e.g. anamoreline and ipamoreline; and growth hormone liberating peptides (GHRPs), e.g. alexamoreline, GHRP-6, hexareline
6° Growth factor derived from platelets (PDGF); vascular endothelial growth factor (VEGF); growth factor similar to insulin-1 (IGF-1) and its analogues; hepatocyte growth factor (HGF); fibroblastic growth factors (FGF); mechanical growth factors (MGF); as well as any other growth factor influencing in muscle, tendon or ligament, protein synthesis/degradation, vascularization, energy use, regenerative capacity or change of fibre type.
III. - Hormonal and metabolic modulators:
1° Modifying agents of myostatin function(s) including but not limited to: myostatin inhibitors.
2° Metabolic modulators:
(a) Activators of the kinase protein activated by the AMP, e.g. AICAR and agonist receptor activated by the prolifers of the δ (PPARδ), e.g. GW 1516;
(b) Insulins;
(c) Trimetazidine.
IV. - Stimulants:
The following stimulants, including all optical isomers, e.g. d- and if applicable, are prohibited:
Adrafinil ; afeepramone ; amphetamine ; amfétaminil ; amiphénazol ; benfluorex ; benzylpipérazine ; bromantan ; clobenzorex ; cocaine ; cropropamide ; crotétamide ; fencamine; penetylline; fenfluramine; fenproporex; fonturacétam [4-phenylpiracétam (carphedon) ] ; furfénorex ; mefénorex ; mephentermine; Mesocarb; metametamine (d-); p- methylamphetamine; modafinil ; norfenfluramine ; phendimétrazine ; phentermine ; prenylamine et prolintane.
Prohibited methods
I. - Handling blood or blood components:
1° Administration or reintroduction of any amount of autologous, allogenic (homologist) or heterogeneous blood or red blood cells of any origin in the circulatory system.
2° Artificial improvement in the consumption, transport or release of oxygen. Includes, but not limited to:
Perfluorinated chemicals; Efaproxiral (RSR13) and modified hemoglobin products, e.g., hemoglobin-based blood substitutes and reticulated hemoglobin-based products, but excluding oxygen supplementation.
3° Any intravascular manipulation of blood or blood component(s) by physical or chemical methods.
II. - Chemical and physical manipulation:
1° Falsification or attempted falsification, with the aim of altering the integrity and validity of samples collected during doping control.
Includes, but not limited to:
The substitution and/or alteration of urine, e.g. proteases;
2° Intravenous infusions and/or injections of more than 50 mL per 6-hour period, except those legitimately received in hospital admissions, surgical procedures or clinical examinations.
III. - Genetic doping:
1° Transfer of nucleic acid polymers or nucleic acid analogs;
2° Use of normal or genetically modified cells.
The decision of 24 November 2014 setting out the list of substances and methods that are prohibited under section L. 232-26 is repealed.
The Sports Director is responsible for the execution of this Order, which will be published in the Official Journal of the French Republic.
Done on January 23, 2015.
For the Minister and by delegation:
The Director of Sports,
T. Mosimann
